Palo Santo Venture Fund

Palo Santo targets the neuroscience and mental health landscape, with a focus on novel CNS therapeutics. This includes next-generation psychedelic therapies advancing through clinical trials and technologies that aim to accelerate precision neuroscience. It invests across stages, from early-stage companies to those with FDA Breakthrough Therapy Designation.

Palo Santo explicitly invests in next-generation psychedelic therapies that are advancing through late-stage clinical trials. It cites multiple programs that have received FDA Breakthrough Therapy Designation, showing significant and durable symptom reduction across depression, PTSD, and women’s mental health. This is one component of its broader CNS and mental health mandate.

The firm has not published individual names, titles, or biographical details for its principals or investment committee. Its website states that the team brings decades of experience in neuroscience, biotech operations, investing, and clinical development, supported by leading academics and scientific advisors, but specific decision-makers are not publicly disclosed.

The firm presents itself as a dedicated venture fund investing across the neuroscience and mental health landscape. It has not disclosed its fund structure, asset size, or whether it operates through committed capital vehicles, special purpose vehicles, or direct balance-sheet investing. Public information is limited to its investment mandate.

Palo Santo’s stated focus covers companies working on treatments for depression, PTSD, and women’s mental health. It cites these as areas where novel therapies have shown significant and durable symptom reduction in clinical trials. The firm also references broader brain health innovation beyond these specific indications.